Page 154 - 南京医科大学自然科学版第1期

第41卷第1期
·148 · 南 京 医 科 大 学 学 报 2021年1月

［28］ Study of pembrolizumab（MK⁃3475）Monotherapy in local⁃ Cancer Care，2016，1（10）：89-97
ly advanced/metastatic renal cell carcinoma（MK ⁃ 3475 ⁃ ［38］ CHAMPIAT S，LAMBOTTE O，BARREAU E，et al. Man⁃
427/KEYNOTE⁃427）［Z/OL］.［2020⁃12⁃08］. https：//clin⁃ agement of immune checkpoint blockade dysimmune tox⁃
icaltrials.gov/ct2/show/NCT02853344?term=NCT0285334 icities：a collaborative position paper［J］. Ann Oncol，
4&draw=2&rank=1 2016，27（4）：559-574
［29］ Safety and efficacy study of pembrolizumab（MK⁃3475）as ［39］ BOUTROS C，AHMAD T，EMILIE R，et al. Safety profiles
monotherapy in the adjuvant treatment of renal cell carci⁃ of anti⁃CTLA⁃4 and anti⁃PD⁃1 antibodies alone and in
noma post nephrectomy（MK⁃3475⁃564/KEYNOTE⁃564） combination［J］. Nat Rev Clin Oncol，2016，13（8）：473-
［Z/OL］.［2020⁃12⁃08］. https：//clinicaltrials.gov/ct2/show/ 486
NCT03142334?term=NCT03142334&draw=2&rank=1 ［40］ WEBER J S，KÄHLER K C，HAUSCHILD A. Manage⁃
［30］ CHOUEIRI T K，ESCUDIER B，POWLES T，et al. Cabo⁃ ment of immune⁃related adverse events and kinetics of re⁃
zantinib versus Everolimus in advanced renal⁃cell carci⁃ sponse with ipilimumab［J］. J Clin Oncol，2012，30（21）：
noma［J］. N Engl J Med，2015，373（19）：1814-1823 2691-2697
［31］ A study comparing the combination of nivolumab and ipil⁃ ［41］ MOSLEHI J J，SALEM J E，SOSMAN J A，et al. Increased
imumab versus placebo in participants with localized renal reporting of fatal immune checkpoint inhibitor⁃associated
cell carcinoma（CheckMate 914）［Z/OL］.［2020 ⁃ 12 ⁃ 08］. myocarditis［J］. Lancet，2018，391（1124）：933
https：//clinicaltrials.gov/ct2/show/NCT03138512?term=N⁃ ［42］ KAO J C，LIAO B，MARKOVIC S N，et al. Neurological
CT03138512&draw=2&rank=1 complications associated with anti ⁃ programmed death 1
［32］ BILUSIC M，MADAN R A，GULLEY J L. Immunotherapy （PD ⁃ 1）antibodies［J］. JAMA Neurol，2017，74（10）：
of prostate cancer：facts and hopes［J］. Clin Cancer Res， 1216-1222
2017，23（22）：6764-6770 ［43］ PALMIERI D J，CARLINO M S. Immune checkpoint in⁃
［33］ DE VELASCO M A，UEMURA H. Prostate cancer immu⁃ hibitor toxicity［J］. Curr Oncol Rep，2018，20（9）：72
notherapy：where are we and where are we going?［J］. ［44］ PUZANOV I，ON BEHALF OF THE SOCIETY FOR IM⁃
Curr Opin Urol，2018，28（1）：15-24 MUNOTHERAPY OF CANCER TOXICITY MANAGE⁃
［34］ MAIA M C，HANSEN A R. A comprehensive review of im⁃ MENT WORKING GROUP，DIAB A，et al. Managing tox⁃
munotherapies in prostate cancer［J］. Crit Rev Oncol He⁃ icities associated with immune checkpoint inhibitors：con⁃
matol，2017，113：292-303 sensus recommendations from the Society for Immunother⁃
［35］ KWON E D，DRAKE C G，SCHER H I，et al. Ipilimumab apy of Cancer（SITC）Toxicity Management Working
versus placebo after radiotherapy in patients with meta⁃ Group［J］. J Immunother Cancer，2017，5（1）：95
static castration ⁃ resistant prostate cancer that had pro⁃ ［45］ ZHU J，ARMSTRONG A J，FRIEDLANDER T W，et al.
gressed after docetaxel chemotherapy（CA184 ⁃ 043）：a Biomarkers of immunotherapy in urothelial and renal cell
multicentre，randomised，double⁃blind，phase 3 trial［J］. carcinoma：PD⁃L1，tumor mutational burden，and beyond
Lancet Oncol，2014，15（7）：700-712 ［J］. J Immunother Cancer，2018，6（1）：4
［36］ BEER T M，KWON E D，DRAKE C G，et al. Randomized， ［46］ TOPALIAN S L，TAUBE J M，ANDERS R A，et al. Mech⁃
double⁃blind，phase Ⅲ trial of ipilimumab versus placebo anism ⁃ driven biomarkers to guide immune checkpoint
in asymptomatic or minimally symptomatic patients with blockade in cancer therapy［J］. Nat Rev Cancer，2016，16
metastatic chemotherapy⁃naive castration⁃resistant pros⁃ （5）：275-287
tate cancer［J］. J Clin Oncol，2017，35（1）：40-47 ［47］ DAVARPANAH N N，YUNO A，TREPEL J B，et al. Im⁃
［37］ FAY A P，MOREIRA R B，FILHO P，et al. The manage⁃ munotherapy：a new treatment paradigm in bladder cancer
ment of immune ⁃ related adverse events associated with ［J］. Curr Opin Oncol，2017，29（3）：184-195
immune checkpoint blockade［J］. Expert Rev Qual Life ［收稿日期］ 2020-06-08